Chronic Kidney Disease At Increased Risk Of Cardiovascular Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for chronic kidney disease at increased risk of cardiovascular disease. 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
6
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Chronic Kidney Disease At Increased Risk Of Cardiovascular Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Lexicon Pharms Inc 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating chronic kidney disease at increased risk of cardiovascular disease. Each bar = one year. Y-axis scaled to peak year (4 patents).

4
28
2
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Inpefa
SOTAGLIFLOZIN
 Lexicon Pharms Inc 6 61 — 2028-05-04

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7781577 Inpefa method of use 83 2028-05-04
7781577 Inpefa method of use 83 2028-05-04
8476413 Inpefa method of use 83 2028-05-29
8476413 Inpefa method of use 83 2028-05-29
8217156 Inpefa composition of matter 18 2030-10-07
8217156 Inpefa composition of matter 18 2030-10-07

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8217156 Inpefa composition of matter 18 2030-10-07
8217156 Inpefa composition of matter 18 2030-10-07
8476413 Inpefa method of use 83 2028-05-29
8476413 Inpefa method of use 83 2028-05-29
7781577 Inpefa method of use 83 2028-05-04
7781577 Inpefa method of use 83 2028-05-04

Related